This slide show features some of the top highlights from the 2015 Society of Gynecologic Oncology Annual Meeting, including a vaccine trial in ovarian cancer and a possible biomarker in advanced cervical cancer.
References:
1. Oh J, Barve M, Grosen EA, et al. Randomized phase II trial of maintenance autologous tumor cell vaccine (FANG™) following clinical complete response (cCR) in stage III/IV ovarian cancer: Preliminary results. 2015 Society of Gynecologic Oncology Annual Meeting. Abstract 1.
2. Coleman RL, Brady MF, Herzog TJ, et al. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213). 2015 Society of Gynecologic Oncology Annual Meeting. Abstract 3.
3. Matulonis UA, Penson RT, Domchek SM, et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multi-study sub-analysis. 2015 Society of Gynecologic Oncology Annual Meeting. Abstract 14.
4. Fuh KC, Java J, Kapp DS, et al. Differences in presentation and survival of Asians versus Caucasians with ovarian cancer: A Gynecologic Oncology Group ancillary study of 7914 patients. 2015 Society of Gynecologic Oncology Annual Meeting. Abstract 9.
5. Tewari KS, Sill M, Monk BJ, et al. Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study. 2015 Society of Gynecologic Oncology Annual Meeting. Abstract 24.
Vaccine Delays Recurrence in Ovarian Cancer:
In a phase II open-label clinical trial, maintenance therapy with Vigil, an autologous tumor cell vaccine, resulted in a delay in disease progression in late-stage ovarian cancer patients. The trial included 31 patients who either received the vaccine (n = 20) or did not (n = 11). Only grade 1 and 2 adverse events were observed. The median recurrence-free survival was 19.3 and 12.4 months in the treatment and control arms, respectively, though the difference was not statistically significant.[1] Image source: Jonathan Oh, MD, Texas Oncology, Dallas, Texas.
Bevacizumab Added to Chemotherapy Improves Progression-Free Survival in Ovarian Cancer:
The Gynecologic Oncology Group 213 trial demonstrated that adding bevacizumab to paclitaxel and carboplatin improved progression-free survival in 674 women with recurrent, platinum-sensitive ovarian cancer. Median progression-free survival was 10.4 and 13.8 months in the control and experimental group, respectively (P
Olaparib Beneficial in Heavily Pretreated Advanced Ovarian Cancer Patients With BRCA Mutations:
A pooled analysis from six prospective clinical trials found that patients with relapsed ovarian, fallopian tube, or peritoneal cancer with germline BRCA mutations had a 36% overall response rate with olaparib monotherapy. The 273 patients included in the analysis had all been previously treated with chemotherapy. The median duration of response was 7.4 months. Among the 205 patients who had previously received three or more lines of chemotherapy (75% of patients), the overall response rate was 31%, and the median duration of response was 7.8 months.[3] Image Caption: Ursula A. Matulonis, MD, Dana-Farber Cancer Institute, Boston, Massachusetts.
Varying Ovarian Cancer Survival Outcomes Among Asian and Caucasian Patients:
Asians enrolled in phase III epithelial ovarian cancer clinical trials had prolonged survival compared with Caucasian patients. Asians tended to present at a younger age (54 vs 59 years, P
High Pretreatment Circulating Tumor Cell (CTC) Count Associated With Higher Survival in Cervical Cancer:
Advanced cervical cancer patients who had higher numbers of CTCs prior to treatment with chemotherapy plus bevacizumab in the Gynecologic Oncology Group 240 phase III clinical trial had higher overall survival. The trial assessed whether CTCs could be a prognostic biomarker. Patients with a high CTC count at 36 days post-treatment had a higher risk of dying. Within the group of patients treated with bevacizumab, the hazard ratio (HR) for death for pre-treatment CTC counts was 0.9. Patients with greater CTC declines had a lower risk of dying (HR = 0.87).[5] Image source: Krishnansu S. Tewari, MD, University of California, Irvine, Medical Center, Orange, California.
